OverviewSuggest Edit

Cosmo Pharmaceuticals is a company that focuses on solutions in the areas of gastroenterology and endoscopy. It formulates and manufactures treatments for the gastro-intestinal tract, specifically inflammatory bowel diseases (IBD), colon infections, and colon diagnosis. The company also provides a system that uses artificial intelligence to detect colorectal polyps and a medical device for the removal of colorectal lesions.
TypePublic
Founded1997
HQDublin 2, IE
Websitecosmopharma.com

Latest Updates

Employees (est.) (Dec 2019)234(-23%)
Revenue (FY, 2019)€62.5 M(-4%)
Share Price (Nov 2020)CHF82.1
Cybersecurity ratingBMore

Key People/Management at Cosmo Pharmaceuticals

Alessandro Della Chà

Alessandro Della Chà

Executive Director, CEO
Eimear Cowhey

Eimear Cowhey

Non-Executive Director
Giuseppe Cipriano

Giuseppe Cipriano

Chief Operating Officer
Luisa Bartorelli

Luisa Bartorelli

Chief Patent Counsel
Davide Malavasi

Davide Malavasi

Qualified Person & Technical Director
Maria Grazia Roncarolo

Maria Grazia Roncarolo

Non-Executive Director
Show more

Cosmo Pharmaceuticals Office Locations

Cosmo Pharmaceuticals has an office in Dublin 2
Dublin 2, IE (HQ)
Riverside 2, Sir John Rogerson's Quay, Dublin Docklands
Show all (1)

Cosmo Pharmaceuticals Financials and Metrics

Cosmo Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Cosmo Pharmaceuticals's revenue was reported to be €62.50 m in FY, 2019 which is a 4.8% decrease from the previous period.
EUR

Revenue (FY, 2019)

62.5m

Revenue growth (FY, 2018 - FY, 2019), %

(4.8%)

Gross profit (FY, 2019)

37.4m

Gross profit margin (FY, 2019), %

59.9%

Net income (FY, 2019)

(24.5m)

EBIT (FY, 2019)

(12.3m)

Market capitalization (12-Nov-2020)

1.2b

Closing stock price (12-Nov-2020)

82.1

Cash (31-Dec-2019)

110.4m

EV

1.2b
Cosmo Pharmaceuticals's current market capitalization is CHF1.2 b.
Annual
EURFY, 2017FY, 2018FY, 2019

Revenue

67.2m65.6m62.5m

Revenue growth, %

(2%)(5%)

Cost of goods sold

22.0m22.1m25.1m

Gross profit

45.3m43.6m37.4m
Half Year
EURH1, 2017H1, 2018H1, 2019

Revenue

31.8m36.7m21.5m

Cost of goods sold

10.7m10.7m11.0m

Gross profit

21.2m25.9m10.5m

Gross profit Margin, %

66%71%49%
Annual
EURFY, 2017FY, 2018FY, 2019

Cash

144.9m210.7m110.4m

Accounts Receivable

13.2m12.8m16.5m

Inventories

3.2m3.9m6.1m

Current Assets

197.3m374.2m302.4m
Half Year
EURH1, 2017H1, 2018H1, 2019

Cash

136.3m84.3m158.4m

Accounts Receivable

15.9m16.2m10.3m

Inventories

3.0m3.9m7.0m

Current Assets

303.3m216.4m351.6m
Annual
EURFY, 2017FY, 2018FY, 2019

Net Income

(32.4m)(17.5m)(21.3m)

Depreciation and Amortization

3.5m4.5m5.8m

Inventories

(937.0k)(696.0k)(2.2m)

Accounts Payable

6.1m(2.7m)(1.0m)
Half Year
EURH1, 2017H1, 2018H1, 2019

Net Income

(19.4m)(5.3m)(22.6m)

Depreciation and Amortization

1.5m2.1m2.6m

Inventories

(666.0k)(706.0k)(3.0m)

Accounts Payable

6.1m(2.7m)(890.0k)
EURH1, 2017

Financial Leverage

1.1 x
Show all financial metrics

Cosmo Pharmaceuticals Operating Metrics

FY, 2017FY, 2018FY, 2019

Drugs in Development

4 5

New Patents

6 10 11

New Trademark Families

7 7 6

Products Marketed

5 5
Show all operating metrics

Cosmo Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
Cristoforo Colombo Real EstateSeptember 26, 2012
BioXellNovember 18, 2009
Aries Pharmaceuticals Inc.
Aries Pharmaceuticals Ltd.
Bellatrix Pharmaceuticals Inc.
Cassiopea S.p.A.
Cosmo Artificial Intelligence
Cosmo S.p.A.
Cosmo Technologies Ltd.
Cosmo Technologies (Three) Ltd.
Show more

Cosmo Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Cosmo Pharmaceuticals Online and Social Media Presence

Embed Graph

Cosmo Pharmaceuticals News and Updates

RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products

TEL-AVIV, Israel and RALEIGH, N.C., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. (SIX: COPN) (“Cosmo”) for a…

Cosmo Pharmaceuticals Blogs

Cosmo Pharmaceuticals Frequently Asked Questions

  • When was Cosmo Pharmaceuticals founded?

    Cosmo Pharmaceuticals was founded in 1997.

  • Who are Cosmo Pharmaceuticals key executives?

    Cosmo Pharmaceuticals's key executives are Alessandro Della Chà, Eimear Cowhey and Giuseppe Cipriano.

  • How many employees does Cosmo Pharmaceuticals have?

    Cosmo Pharmaceuticals has 234 employees.

  • What is Cosmo Pharmaceuticals revenue?

    Latest Cosmo Pharmaceuticals annual revenue is €62.5 m.

  • What is Cosmo Pharmaceuticals revenue per employee?

    Latest Cosmo Pharmaceuticals revenue per employee is €267.1 k.

  • Who are Cosmo Pharmaceuticals competitors?

    Competitors of Cosmo Pharmaceuticals include TRB Chemedica, PhaseBio Pharmaceuticals and Nomax.

  • Where is Cosmo Pharmaceuticals headquarters?

    Cosmo Pharmaceuticals headquarters is located at Riverside 2, Sir John Rogerson's Quay, Dublin Docklands, Dublin 2.

  • Where are Cosmo Pharmaceuticals offices?

    Cosmo Pharmaceuticals has an office in Dublin 2.

  • How many offices does Cosmo Pharmaceuticals have?

    Cosmo Pharmaceuticals has 1 office.